Neurotensin regulates intracellular calcium in ventral tegmental area astrocytes: evidence for the involvement of multiple receptors

Neuroscience. 2000;97(2):293-302. doi: 10.1016/s0306-4522(99)00597-7.

Abstract

Recent evidence suggests that some types of neurotensin receptors may be expressed by astrocytes. In order to explore the function of neurotensin receptors in astrocytes, the effect of a neurotensin receptor agonist, neurotensin(8-13), on intracellular Ca(2+) dynamics in mixed neuronal/glial cultures prepared from rat ventral tegmental area was examined. It was found that neurotensin(8-13) induces a long-lasting rise in intracellular Ca(2+) concentration in a subset of glial fibrilary acidic protein-positive glial cells. This response displays extensive desensitization and appears to implicate both intracellular and extracellular Ca(2+) sources. In the absence of extracellular Ca(2+), neurotensin(8-13) evokes only a short-lasting rise in intracellular Ca(2+). The neurotensin-evoked intracellular Ca(2+) accumulation is blocked by the phospholipase C inhibitor U73122 and by thapsigargin, suggesting that it is initiated by release of Ca(2+) from an inositol triphosphate-dependent store. The Ca(2+)-mobilizing action of neurotensin(8-13) in astrocytes is dependent on at least two receptors, because the response is blocked in part only by SR48692, a type 1 neurotensin receptor antagonist, and is blocked completely by SR142948A, a novel neurotensin receptor antagonist. The finding that the type 2 neurotensin receptor agonist levocabastine fails to mimic or alter the effects of neurotensin(8-13) on intracellular Ca(2+) makes it unlikely that the type 2 neurotensin receptor is involved. In summary, these results show that functional neurotensin receptors are present in cultured ventral tegmental area astrocytes and that their activation induces a highly desensitizing rise in intracellular Ca(2+). The pharmacological profile of this response suggests that a type 1 neurotensin receptor is involved but that another, possibly novel, non-type 2 neurotensin receptor is also implicated. If present in vivo, such signalling could be involved in some of the physiological actions of neurotensin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adamantane / analogs & derivatives
  • Adamantane / pharmacology
  • Animals
  • Animals, Newborn
  • Astrocytes / cytology
  • Astrocytes / drug effects
  • Astrocytes / physiology*
  • Calcium / metabolism*
  • Cells, Cultured
  • Estrenes / pharmacology
  • Gadolinium / pharmacology
  • Imidazoles / pharmacology
  • Neurotensin / pharmacology*
  • Peptide Fragments / pharmacology*
  • Piperidines / pharmacology
  • Pyrrolidinones / pharmacology
  • Rats
  • Receptors, Neurotensin / antagonists & inhibitors
  • Receptors, Neurotensin / physiology*
  • Thapsigargin / pharmacology
  • Type C Phospholipases / antagonists & inhibitors
  • Ventral Tegmental Area / cytology
  • Ventral Tegmental Area / physiology*

Substances

  • Estrenes
  • Imidazoles
  • Peptide Fragments
  • Piperidines
  • Pyrrolidinones
  • Receptors, Neurotensin
  • SR 142948A
  • 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione
  • Neurotensin
  • neurotensin (8-13)
  • Thapsigargin
  • Gadolinium
  • Type C Phospholipases
  • levocabastine
  • Adamantane
  • Calcium